These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 32765257)

  • 1. Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia.
    Martel JC; Gatti McArthur S
    Front Pharmacol; 2020; 11():1003. PubMed ID: 32765257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of radioligands in schizophrenia research.
    Sedvall G; Farde L; Hall H; Halldin C; Karlsson P; Nordström AL; Nyberg S; Pauli S
    Clin Neurosci; 1995; 3(2):112-21. PubMed ID: 7583617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D4 receptors and development of newer antipsychotic drugs.
    Kulkarni SK; Ninan I
    Fundam Clin Pharmacol; 2000; 14(6):529-39. PubMed ID: 11206702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D2S, D2L, D3, and D4 dopamine receptors couple to a voltage-dependent potassium current in N18TG2 x mesencephalon hybrid cell (MES-23.5) via distinct G proteins.
    Liu LX; Burgess LH; Gonzalez AM; Sibley DR; Chiodo LA
    Synapse; 1999 Feb; 31(2):108-18. PubMed ID: 10024007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The physiology, signaling, and pharmacology of dopamine receptors.
    Beaulieu JM; Gainetdinov RR
    Pharmacol Rev; 2011 Mar; 63(1):182-217. PubMed ID: 21303898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of dopamine receptor subtypes in mediating modulation of T lymphocyte function.
    Huang Y; Qiu AW; Peng YP; Liu Y; Huang HW; Qiu YH
    Neuro Endocrinol Lett; 2010; 31(6):782-91. PubMed ID: 21196914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons.
    Centonze D; Grande C; Usiello A; Gubellini P; Erbs E; Martin AB; Pisani A; Tognazzi N; Bernardi G; Moratalla R; Borrelli E; Calabresi P
    J Neurosci; 2003 Jul; 23(15):6245-54. PubMed ID: 12867509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
    Wilson JM; Sanyal S; Van Tol HH
    Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The peripheral dopaminergic system: morphological analysis, functional and clinical applications.
    Amenta F; Ricci A; Tayebati SK; Zaccheo D
    Ital J Anat Embryol; 2002; 107(3):145-67. PubMed ID: 12437142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine receptor pharmacology.
    Seeman P; Van Tol HH
    Curr Opin Neurol Neurosurg; 1993 Aug; 6(4):602-8. PubMed ID: 8104554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular neurobiology of dopaminergic receptors.
    Sibley DR; Monsma FJ; Shen Y
    Int Rev Neurobiol; 1993; 35():391-415. PubMed ID: 8463063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms.
    Liu LX; Monsma FJ; Sibley DR; Chiodo LA
    Synapse; 1996 Oct; 24(2):156-64. PubMed ID: 8890457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.
    Luedtke RR; Rangel-Barajas C; Malik M; Reichert DE; Mach RH
    Curr Pharm Des; 2015; 21(26):3700-24. PubMed ID: 26205291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in D1/D2 synergism may account for enhanced stereotypy and reduced climbing in mice lacking dopamine D2L receptor.
    Fetsko LA; Xu R; Wang Y
    Brain Res; 2003 Mar; 967(1-2):191-200. PubMed ID: 12650980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I] 2'-iodospiperone.
    Leysen JE; Gommeren W; Mertens J; Luyten WH; Pauwels PJ; Ewert M; Seeburg P
    Psychopharmacology (Berl); 1993; 110(1-2):27-36. PubMed ID: 7870895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine receptors and antipsychotic drug response.
    Sunahara RK; Seeman P; Van Tol HH; Niznik HB
    Br J Psychiatry Suppl; 1993 Dec; (22):31-8. PubMed ID: 7906523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands.
    Viaro R; Calcagno M; Marti M; Borrelli E; Morari M
    Neuropharmacology; 2013 Sep; 72():126-38. PubMed ID: 23643745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance.
    Maggio R; Aloisi G; Silvano E; Rossi M; Millan MJ
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S2-7. PubMed ID: 20123551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptor pharmacology.
    Seeman P; Van Tol HH
    Trends Pharmacol Sci; 1994 Jul; 15(7):264-70. PubMed ID: 7940991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.